-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Author Index: E

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Eder, M.
505 - Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
847 - Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia
851 - Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party
2161 - Comparative Safety and Efficacy of Posttransplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Cardiovascular Comorbidity Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission from Unrelated Donors: A Retrospective Pair-Match Analysis of EBMT ALWP
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4895 - Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
Eichhorst, B. F.
761 - Polyfunctional Effector PD-1+ CD8+ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
1009 - Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
1846 - In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment
1859 - Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
3250 - Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)
4608 - Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents
4613 - Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
4618 - Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) – Primary Endpoint Analysis of the Phase II CLL-Frail Trial
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
Einsele, H.
284 - Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations
487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
593 - Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab
708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
1952 - The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
2018 - Local Myeloid Network Resilience Determines Organ-Specific Acute GvHD Outcomes
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
3010 - Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström’s Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)
3267 - GPRC5D Status Impacts CD38 Expression in Multiple Myeloma
3397 - TNFR2, GITR and DR3 Agonists Exert Distinct Response Durations in Treg-Mediated Acute Graft-Versus-Host Disease Protection
3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
4639 - Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia
4665 - CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4705 - Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma
4714 - Early Detection and Monitoring of Multiple Myeloma By a Blood-Based Multi-Transcript Molecular Signature
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
Eisfeld, A. K.
327 - Phip Is a Potent Leukemia Oncogene Identified in Acute Myeloid Leukemia (AML) Patients of African Ancestry
641 - Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment
951 - CRISPR/RfxCas13d Screening Identifies the Long Non-Coding RNA (LncRNA) Nfyc-AS1 As a Molecular Vulnerability in Acute Myeloid Leukemia (AML)
954 - A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR::ABL-Positive Leukemias
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
2922 - A Rapid Diagnostic Assay to Detect a DNA Methylation Signature of Menin Inhibitor Response in Acute Myeloid Leukemia
3801 - Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium
4286 - A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
4304 - Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)
- Risk Re-Stratification Based on Black AML Patient Exome Data
Eleutherakis-Papaiakovou, E.
361 - Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4715 - Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
Elmariah, H.
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
Epperla, N.
398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
864 - 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
985 - Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration
1719 - Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
2375 - Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
3737 - Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM)
3745 - Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States
3747 - Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
4350 - Transcriptomic Analysis in Mantle Cell Lymphoma Patients Identified MALAT1 Long-Non-Coding RNA to Regulate Cell Cycle Progression By Modulating EZH2/p57/Sox11 Axis
4371 - Tumor Microenvironment-Induced Interleukin-6 Regulates Proliferation and Survival in Patients with Mantle Cell Lymphoma (MCL) By Activating FGFR1 Signaling
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study
5119 - Trends in Incidence and Survival of Patients with Primary Effusion Lymphoma in the United States
- International Medical Graduates
Epstein-Peterson, Z. D.
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
340 - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4433 - Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
Erba, H. P.
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
1509 - Anchored Matching Adjusted Indirect Treatment Comparison of Quizartinib Vs Midostaurin in Newly Diagnosed Patients with FLT3-ITD-Positive Acute Myeloid Leukaemia
1530 - 4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)
2414 - Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024
4282 - Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
4309 - Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG
Esteve, J.
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
225 - Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations
598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
787 - Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project
851 - Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party
962 - Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
3510 - Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients
4285 - Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z